Safety and Efficacy of Corneal Crosslinking Treatment in Children with Keratoconus
Abstract
Keywords
Kaynakça
- 1.Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998; 42(4):297-319.
- 2.El-Khoury S, Abdelmassih Y, Hamade A, Slim E, Cherfan CG, Chelala E, et al. Pediatric keratoconus in a tertiary referral center: incidence, presentation, risk factors, and treatment. J Refract Surg. 2016; 32(8):534-41.
- 3.Sabti S, Tappeiner C, Frueh BE. Corneal cross-linking in a 4-year-old child with keratoconus and Down syndrome. Cornea. 2015; 34(9):1157-60.
- 4.Vinciguerra P, Albe E, Frueh BE, Trazza S, Epstein D. Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus. Am J Ophthalmol. 2012; 154(3):520-6.
- 5.Leoni-Mesplie S, Mortemousque B, Touboul D, Malet F, Praud D, Mesplie N, et al. Scalability and severity of keratoconus in children. Am J Ophthalmol. 2012; 154(1):56-62.
- 6.Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the teratment of keratoconus. Am J Ophthalmol. 2003; 135(5):620-7.
- 7.O’Brart DP, Kwong TQ, Patel P, McDonald RJ, O’Brart NA. Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus. Br J Ophthalmol.2013; 97(4):433-7.
- 8.Ghanem RC, Santhiago MR, Berti T, Netto MV, Ghanem VC. Topographic, corneal wavefront and refractive outcomes 2 years after collgen crosslinking for progressive keratoconus. Cornea. 2014; 33(1):43-51.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Klinik Tıp Bilimleri
Bölüm
Araştırma Makalesi
Yazarlar
Sait Coşkun Özcan
0000-0002-0608-9371
Türkiye
Yayımlanma Tarihi
28 Nisan 2021
Gönderilme Tarihi
22 Şubat 2021
Kabul Tarihi
15 Mart 2021
Yayımlandığı Sayı
Yıl 2021 Cilt: 18 Sayı: 1